Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that Patrick Vink, M.D., has joined the Company as Senior Vice President and General Manager of its International Business. In this new position reporting to Cubist President and COO Robert J. Perez, Dr. Vink will oversee Cubist’s commercial opportunities across Europe and in select developing markets, as well as global partnerships.
Dr. Vink brings 25 years of global industry experience to Cubist, most recently serving as Senior Vice President, Global Head of Hospital Business and Global Head of Biologics for Mylan Inc. In this role, Dr. Vink coordinated all hospital business of the company. He joined Mylan in 2008, and established the company’s operations in Switzerland, which was the basis of a number of global functions. Dr. Vink was also responsible for the company’s biosimilars market entry.
Prior to Mylan, Dr. Vink held several leadership positions across the industry, including Head of Business Franchise Biopharmaceuticals for Novartis Sandoz; Director, Central Europe and VP International Sales for Biogen; and Head of Worldwide Marketing, Cardiovascular and Thrombosis for Sanofi-Synthelabo.
“Patrick brings extensive global experience to Cubist. His deep understanding of the international markets and strong track record of commercial success – including the launch of several blockbuster products – will be a tremendous asset to Cubist as we develop and implement our international strategy,” said Perez. “I also know Patrick to be a dynamic and insightful leader who shares Cubist’s dedication to innovation and collaboration. I am confident that he will make a great additional to our leadership team.”“This is an incredible time to be joining Cubist,” said Dr. Vink. “The company has great momentum and the wind at its back as it looks to grow its business and expand its global presence. I’m delighted to be joining the ranks of Cubist’s talented team and look forward to working with the organization to build and develop its international business.”
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV